Biosimilars could lead to over $130 billion in savings by 2025, giving 1.2 million patients access to needed medicines.
Dr. Janet Woodcock will bring invaluable insights on generics and biosimilars during this public health emergency. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings.
Hear the latest from top-in-their-field speakers and government officials, connect with peers from around the world and explore new learning tracks in the generics and biosimilars industry. November 8-10, 2021. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings!
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.
Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.
Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.
Find an up-to-date list of FDA approved biosimilars and launches.
These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.
Recent Tweets
Thanks to these three bills in Congress, American patients are one step closer to greater access to lifesaving #biosimilars.
✅ The BIOSIM Act
✅ The Increasing Access to Biosimilars Act
✅ The Ensuring Access to Lower-Cost Medicines for Seniors Act
https://bit.ly/3i7Klhi
601 New Jersey Ave NW, Suite 850
Washington DC 20001
E: [email protected]
P: 202.249.7100
©2020 Biosimilars Council
Biosimilars Council is a division of the Association for Accessible Medicines.
